PHG

Koninklijke Philips NV ADR
NYSEHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$24.32B
P/E Ratio
22.95
EPS
$1.09
Beta
0.92
52W High
$32.19
52W Low
$23.85
50-Day MA
$26.60
200-Day MA
$27.89
Dividend Yield
3.87%
Profit Margin
5.50%
Forward P/E
14.71
PEG Ratio
0.88

About Koninklijke Philips NV ADR

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$17.64B
Gross Profit (TTM)$7.97B
EBITDA$2.09B
Operating Margin6.17%
Return on Equity8.36%
Return on Assets3.48%
Revenue/Share (TTM)$18.57
Book Value$13.12
Price-to-Book1.96
Price-to-Sales (TTM)1.38
EV/Revenue1.588
EV/EBITDA10.47
Quarterly Earnings Growth (YoY)97.20%
Quarterly Revenue Growth (YoY)-4.70%
Shares Outstanding$971.98M
Float$951.23M
% Insiders0.00%
% Institutions5.55%

Historical Volatility

HV 10-Day
34.82%
HV 20-Day
32.16%
HV 30-Day
28.99%
HV 60-Day
27.21%
HV Rank
54.0%

Volatility is currently expanding

Analyst Ratings

Consensus ($33.26 target)
2
Strong Buy
3
Hold

Latest News

Philips Shares Fall After Orders Slip

Shares in Philips fell as much as 11% in early European morning trade, wiping out the stock's gains since the start of the year.

WSJ7/28/2026Negative
Koninklijke Philips Q2 Earnings Call Highlights

Koninklijke Philips NYSE: PHG reported 4.1% comparable sales growth in the second quarter of 2026, supported by growth across all segments, while maintaining its full-year underlying sales and profitability outlook amid higher tariffs, cost inflation and continued weakness in China's health systems market.

MarketBeat7/28/2026Neutral
Philips delivers solid comparable sales growth and margin in Q2; reiterates full year comparable sales growth outlook; Adjusted EBITA and free cash flow outlook increased to reflect US tariff refund

July 27, 2026 Q2 2026 Group performance Comparable order intake declined 1%, due to timing of certain large orders Group sales of EUR 4.4 billion, reflecting 4% comparable sales growth Income from operations of EUR 609 million, including US tariff refund benefit of EUR 186 million Adjusted EBITA margin increased to 16.4%, including US tariff refund benefit of effectively 4.2% Operating cash flow of EUR 376 million, with free cash flow of EUR 222 million including receipt of US tariff refund 2026 comparable sales growth outlook reiterated; Adjusted EBITA and free cash flow outlook updated to reflect US tariff refund Roy Jakobs, CEO of Royal Philips: “We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments, and strong disciplined execution within an uncertain macro environment. Customer demand for our innovations remains healthy, with certain large orders in North America shifting into the third quarter, while Europe delivered strong double-digit order growth.

GlobeNewsWire7/27/2026Neutral
Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor

July 21, 2026 New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation. Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company's ongoing commitment to providing clinicians with trusted oxygen saturation measurements that support confident care for every patient.

GlobeNewsWire7/21/2026Neutral
Philips introduces Alturion ultrasound system with AI-powered workflows for high-volume clinical environments

July 8, 2026 Newest addition to the Philips ultrasound portfolio, Alturion recently received FDA 510(k) clearance and CE mark, expanding access to advanced imaging and workflow innovation across clinical settings Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Alturion ultrasound system with AI-powered workflow built for high-volume settings. Available in the USA and Europe following FDA 510(k) clearance and CE mark certification, Alturion helps clinicians work more efficiently, deliver consistent results, and make confident clinical decisions.

GlobeNewsWire7/8/2026Neutral
University Health in San Antonio selects Philips enterprise monitoring platform to transform patient monitoring and advance system-wide standardization as patient volume grows

CAMBRIDGE, Mass. & SAN ANTONIO--(BUSINESS WIRE)--Royal Philips, a global leader in health technology, and University Health in San Antonio today announced a strategic contract to modernize and standardize patient monitoring through Philips' Enterprise Monitoring as a Service (EMaaS) model. The collaboration will transition University Health in San Antonio to a fully integrated Philips monitoring platform environment, supporting clinical workflows, alarm management initiatives and data-driven de.

Business Wire6/29/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PHG and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026